Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages

Bristol Myers Squibb Company (NYSE:BMY) has been given a consensus rating of “Hold” by the nineteen brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $61.25.

A number of research firms have issued reports on BMY. Guggenheim reiterated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Cantor Fitzgerald restated a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a report on Monday, July 6th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Weiss Ratings reiterated a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. Finally, UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th.

Institutional Trading of Bristol Myers Squibb

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after acquiring an additional 2,743,759 shares during the period. State Street Corp boosted its holdings in Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after acquiring an additional 1,385,206 shares during the period. Geode Capital Management LLC grew its position in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Norges Bank acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $1,947,272,000. Finally, AQR Capital Management LLC increased its stake in shares of Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

BMY opened at $60.47 on Friday. The firm has a market capitalization of $123.48 billion, a P/E ratio of 16.99, a PEG ratio of 0.17 and a beta of 0.23. The stock has a fifty day moving average of $56.93 and a 200-day moving average of $57.76. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts forecast that Bristol Myers Squibb will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, a meaningful regulatory step that supports the company’s oncology pipeline and future revenue potential. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusually heavy call option buying suggested traders were positioning for further upside in BMY, with call volume well above normal levels.
• Positive Sentiment: Recent coverage highlighted Bristol Myers Squibb as a strong value stock and noted that its earnings surprise history could support another potential beat in the next quarterly report. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: BMY continued to attract investor attention and broad market discussion, which can amplify trading interest even without a specific new catalyst. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Wells Fargo reportedly assigned a Hold rating, and one market note said the stock underperformed peers earlier in the week, which may have tempered some enthusiasm. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.